Drugs / Metyrapone
Metyrapone
also known as
Metopirone · Metirapona · Metopiron · Metopirone ditartrate · Metyrapone also known as Metopirone · METYRAPONE TARTRATE · MRP · NSC-25265 · +1 more
Small molecule targets CYP11B1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | METOPIRONE | — | 1961-12-04 | fda.gov ↗ |
Trials 16 · a red edge is where a trial was stopped
19601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030203120322033
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05919992 | May 2023 → Jul 2024 | glucocorticoid therapy, response to | Eleonora Seelig | Completed | No outcome recorded |
| Phase 0 | NCT05167084 | Feb 2022 → Jun 2023 | glucocorticoid therapy, response to | Eleonora Seelig | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT03404817 | Mar → Jun 2018 | substance-related disorder | Embera NeuroTherapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02856854 | Jul 2016 → Feb 2017 | substance-related disorder | Embera NeuroTherapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01673087 | Oct 2012 → Aug 2017 | — | University of Michigan | Completed | No outcome recorded |
| Phase 1 | NCT00033098 | Nov 2001 → May 2002 | cocaine dependence | National Institute on Drug Abuse (NIDA) | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04933916 | Jun 2021 → Apr 2023 | nicotine dependence | Embera NeuroTherapeutics, Inc. | Terminated | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07138274 | Aug 2026 → Jun 2031 expected | ACTH-independent Cushing syndrome | Mayo Clinic | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06106295 | Dec 2023 → Jan 2028 expected | ACTH-independent Cushing syndrome | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04501874 | Jul 2020 → Jul 2022 | substance-related disorder | Embera NeuroTherapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00125554 | May 1998 → Jul 2001 | major depressive disorder | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04868253 | May → Dec 2021 | nicotine dependence | Rose Research Center, LLC | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02297945 | Apr 2015 → Nov 2019 | Cushing syndrome | HRA Pharma | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07268222 | Dec 2025 → Nov 2026 expected | ACTH-independent Cushing syndrome | Laiko General Hospital, Athens | Recruiting | No outcome recorded |
| Phase 4 | NCT03491696 | Dec 2018 → Jun 2022 | depressive disorder | Centre Hospitalier Rouffach | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06556277 | Sep 2024 → Feb 2026 | overnutrition | Eleonora Seelig | Completed | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02406066 Comparator | Mar → Dec 2015 | substance-related disorder | Embera NeuroTherapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00426608 Background | Oct 2006 → Jan 2007 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01375920 Comparator | Feb 2011 → Feb 2013 | depressive disorder | Jane Barnes | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07494084 Comparator | Jul 2026 → Mar 2029 expected | circadian rhythm sleep disorder, shift work type | Washington State University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT01620684 Comparator | Feb 2013 → Dec 2014 | metabolic syndrome X, obesity disorder | Baker Heart Research Institute | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00567814 Comparator | Dec 2007 → Nov 2008 | cocaine dependence | Embera NeuroTherapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metyrapone | “EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®;...” NCT04933916 ↗21“EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®;...” NCT04501874 ↗ “EMB-001 is a proprietary combination of metyrapone (a cortisol synthesis inhibitor) and oxazepam (a short to medium acting benzodiazepine).” NCT04868253 ↗ “EMB-001 is a combination of metyrapone (720mg per dose in this study) and oxazepam (24mg per dose in this study)” NCT02856854 ↗ “This is a study of EMB-001 (a combination of two FDA-approved drugs, metyrapone and oxazepam) in healthy adults.” NCT03404817 ↗ |
| Known as | Metirapona | ChEMBL registry synonym — accepted as the source's own label CHEMBL934 ↗ |
| Known as | Metopiron | ChEMBL registry synonym — accepted as the source's own label CHEMBL934 ↗ |
| Known as | Metopirone | “EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®;...” NCT04933916 ↗1“EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®;...” NCT04501874 ↗ |
| Known as | Metopirone ditartrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL934 ↗ |
| Known as | Metyrapone also known as Metopirone | “Metyrapone also known as Metopirone” NCT01375920 ↗ |
| Known as | METYRAPONE TARTRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL934 ↗ |
| Known as | MRP | “To evaluate the safety of metyrapone (MRP) for using in an outpatient study in which participants would be given 2 750 mg doses of MRP per week.” NCT00033098 ↗ |
| Known as | NSC-25265 | ChEMBL registry synonym — accepted as the source's own label CHEMBL934 ↗ |
| Known as | SU-4885 | ChEMBL registry synonym — accepted as the source's own label CHEMBL934 ↗ |
| Action | Inhibit | “this compound inhibits selectively the 11β-hydroxylase and the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1)” NCT00125554 ↗1“Cytochrome P450 11B1, mitochondrial inhibitor” CHEMBL934 ↗ |
| Modality | Small molecule | — CHEMBL934 ↗ |
| Route | Oral | “to be taken orally” NCT01375920 ↗ |
| Target | CYP11B1 | “Cytochrome P450 11B1, mitochondrial inhibitor” CHEMBL934 ↗ |